Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-786 for Agitation in Alzheimer's Dementia
NCT04408755Phase 3Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of deudextromethorphan in agitation, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jul 2020; status: terminated.
02
Drugs
deudextromethorphan
03
Conditions
agitation
Beyond the preview
Go deeper on NCT04408755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04408755.